최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.23 no.10 = no.162, 2013년, pp.1216 - 1222
허웅 (부산대학교 의학전문대학원 생화학교실) , 이영신 (부산대학교 의학전문대학원 생화학교실) , 배재호 (부산대학교 의학전문대학원 생화학교실)
NK cells are lymphoid immune cells that participate in innate immunity to protect against foreign pathogens and transforming cells. It is known that the activity of NK cells is regulated by a balance between activating and inhibitory signals rather than specific antigens. One important activating si...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Bae, J. H., Kim, J. Y., Kim, M. J., Chang, S. H., Park, Y. S., Son, C. H., Park, S. J., Chung, J. S., Lee, E. Y., Kim, S. H. and Kang, C. D. 2010. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother 33, 391-401.
Bae, J. H., Kim, S. J., Kim, M. J., Oh, S. O., Chung, J. S., Kim, S. H. and Kang, C. D. 2012. Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci 103, 7-16.
Campoli, M. and Ferrone, S. 2008. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72, 321-334.
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998.
Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A. and Zwirner, N. W. 2008. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180, 4606-4614.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E., DeFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M. H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R., Futreal, P. A. and Stratton, M. R. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158.
Mazieres, J., He, B., You, L., Xu, Z. and Jablons, D. M. 2005. Wnt signaling in lung cancer. Cancer Lett 222, 1-10.
Minamoto, T., Mai, M. and Ronai, Z. 2000. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. Cancer Detect Prev 24, 1-12.
Molinero, L. L., Domaica, C. I., Fuertes, M. B., Girart, M. V., Rossi, L. E. and Zwirner, N. W. 2006. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 67, 170-182.
Nesbit, C. E., Tersak, J. M. and Prochownik, E. V. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18, 3004-3016.
Park, S. W., Bae, J. H., Kim, S. D., Son, Y. O., Kim, J. Y., Park, H. J., Lee, C. H., Park, D. Y., Lee, M. K., Chung, B. S., Kim, S. H. and Kang, C. D. 2007. Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest 25, 299-307.
Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S. H., Masiarz, F. R., Munemitsu, S. and Polakis, P. 1993. Association of the APC gene product with beta-catenin. Science 262, 1731-1734.
Salih, J., Hilpert, J., Placke, T., Grunebach, F., Steinle, A., Salih, H. R. and Krusch, M. 2010. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 127, 2119-2128.
Shimizu, H., Julius, M. A., Giarre, M., Zheng, Z., Brown, A. M. and Kitajewski, J. 1997. Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth Differ 8, 1349-1358.
Smyth, M. J., Hayakawa, Y., Takeda, K. and Yagita, H. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2, 850-861.
Takebe, N., Harris, P. J., Warren, R. Q. and Ivy, S. P. 2011. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8, 97-106.
Van Scoyk, M., Randall, J., Sergew, A., Williams, L. M., Tennis, M. and Winn, R. A. 2008. Wnt signaling pathway and lung disease. Transl Res 151, 175-180.
Vita, M. and Henriksson, M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16, 318-330.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.